Kintara Therapeutics, Inc.

Equities

KTRA

US49720K2006

Biotechnology & Medical Research

Real-time Estimate Cboe BZX 03:21:12 2024-03-28 pm EDT 5-day change 1st Jan Change
0.102 USD +13.97% Intraday chart for Kintara Therapeutics, Inc. +11.48% -39.86%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Kintara Therapeutics Announces Expansion of REM-001 Clinical Study to Include Patients on Pembrolizumab CI
Kintara Therapeutics Continues to Evaluate Strategic Options CI
Kintara Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended December 31, 2023 CI
Kintara Therapeutics, Inc. Announces Initiation of Rem-001 Clinical Trial for the Treatment of Cutaneous Metastatic Breast Cancer CI
Wall Street Set for Cautious Opening in Final Trading Day of a Bullish 2023 MT
Index Futures Edge Higher to End Mostly Positive Year on High Note MT
Top Premarket Gainers MT
Kintara Therapeutics Initiates Strategic Review to Optimize Shareholder Value MT
Kintara Therapeutics Initiates Review of Strategic Alternatives CI
Kintara Therapeutics, Inc. Announces Executive Changes CI
Kintara Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended September 30, 2023 CI
Health Care Up Slightly Amid Mixed Earnings -- Health Care Roundup DJ
Sector Update: Health Care Stocks Rise Late Afternoon MT
Sector Update: Health Care MT
Top MIdday Decliners MT
Kintara Therapeutics Announces Preliminary Topline Results from GBM AGile Study CI
Kintara Therapeutics, Inc. Presents Case Studies of Glioblastoma Patients Treated with VAL-083 at 2023 European Association for Neuro-Oncology Annual Meeting CI
Kintara Therapeutics, Inc. Reports Earnings Results for the Full Year Ended June 30, 2023 CI
Transcript : Kintara Therapeutics, Inc. - Special Call
Maxim Upgrades Kintara Therapeutics to Buy From Hold With $14 Price Target MT
Bank Stocks Lift Exchange-Traded Funds, Equity Futures Pre-Bell Thursday After Stress Test Results MT
Kintara Therapeutics Shares Up 19% After NIH Grant DJ
Top Premarket Gainers MT
Kintara Therapeutics Receives $2 Million Grant for Development Program of Cancer Treatment Agent MT
Kintara Therapeutics, Inc. Announces CFO Changes CI
Chart Kintara Therapeutics, Inc.
More charts
Kintara Therapeutics, Inc. is a clinical-stage, biopharmaceutical company that is focused on the development and commercialization of new cancer therapies. It is focused on the development of novel cancer therapies for patients with unmet medical needs. Its two candidates include VAL-083 and REM-001. VAL-083 is a novel, validated, deoxyribonucleic acid (DNA)-targeting agent, for the treatment of drug-resistant solid tumors, such as glioblastoma multiforme (GBM) and potentially other solid tumors, including ovarian cancer, non-small cell lung cancer (NSCLC), and diffuse intrinsic pontine glioma (DIPG). REM-001 is a late-stage photodynamic therapy (PDT) for the treatment of cutaneous metastatic breast cancer (CMBC), basal cell carcinoma nevus syndrome (BCCNS), and access graft failure in hemodialysis patients. VAL-083 is being evaluated in all three GBM patient subtypes in the GBM AGILE Study: newly diagnosed methylated MGMT; newly diagnosed unmethylated MGMT, and recurrent.
More about the company
  1. Stock
  2. Equities
  3. Stock Kintara Therapeutics, Inc. - Nasdaq
  4. News Kintara Therapeutics, Inc.
  5. Sector Update: Health Care Stocks Edging Higher This Afternoon